NEW YORK, July 17, 2015 /PRNewswire/ -- Seeger Weiss LLP is currently investigating cases of patients who claim to have suffered heart failure after using the prescription drug Onglyza, a medicine prescribed to treat Type 2 diabetes. This follows an April 2015 recommendation by an Advisory Committee to the U.S. Food and Drug Administration (FDA) that the Agency require a warning on the Onglyza label for a possible increased risk of heart failure in patients using the drug.
The panel made their recommendation after a review of data from the SAVOR study, which was conducted by AstraZeneca, the manufacturer of Onglyza. The study found a 27 percent increased risk of heart failure and death in patients taking Onglyza. The FDA requested that AstraZeneca study the cardiovascular safety of Onglyza after a 2013 article published in the New England Journal of Medicine found a possible association between the use of saxagliptin, the active ingredient in Onglyza, and heart failure.
Fourteen of the fifteen panelists participating in the FDA Advisory Committee voted to update the warning label on Onglyza, while one panelist voted to withdraw the drug from the U.S. market altogether. The FDA has not advised patients to stop using the drug but this recent study may be cause for patients to reevaluate their drug choice with their doctor.
Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.
SOURCE Seeger Weiss LLP